Analyst Price Targets — EDIT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 5, 2026 8:46 pm | — | Chardan Capital | $4.00 | $3.04 | TheFly | Editas Medicine price target raised to $4 from $3.50 at Chardan |
| March 9, 2026 8:22 pm | — | Robert W. Baird | $6.00 | $2.32 | StreetInsider | Baird Reiterates Outperform Rating on Editas Medicine (EDIT) following earnings |
| November 5, 2024 10:23 am | Gena Wang | Barclays | $5.00 | $3.12 | StreetInsider | Editas Medicine (EDIT) PT Lowered to $5 at Barclays |
| October 23, 2024 6:36 am | Yanan Zhu | Wells Fargo | $9.00 | $3.29 | StreetInsider | Editas Medicine (EDIT) PT Lowered to $9 at Wells Fargo |
| October 22, 2024 1:41 pm | Joel Beatty | Robert W. Baird | $10.00 | $3.29 | StreetInsider | Editas Medicine (EDIT) PT Lowered to $10 at Baird |
| August 8, 2024 7:24 am | Joon Lee | Truist Financial | $12.00 | $4.24 | StreetInsider | Editas Medicine (EDIT) PT Lowered to $12 at Truist Securities |
| August 8, 2024 6:44 am | Greg Harrison | Bank of America Securities | $15.00 | $4.21 | StreetInsider | BofA Securities Upgrades Editas Medicine (EDIT) to Buy |
| May 30, 2024 6:02 am | Liisa Bayko | Evercore ISI | $7.00 | $5.10 | StreetInsider | Editas Medicine (EDIT) PT Lowered to $7 at Evercore ISI |
| May 9, 2024 12:34 am | Matthew Harrison | Morgan Stanley | $7.00 | $5.04 | StreetInsider | Morgan Stanley Upgrades Editas Medicine (EDIT) to Equalweight |
| September 28, 2023 4:38 pm | Dae Gon Ha | Stifel Nicolaus | $17.00 | $6.92 | StreetInsider | Stifel Upgrades Editas Medicine (EDIT) to Buy, 'Difficult To Justify Current Valuation' |
Latest News for EDIT
BlackRock Inc. acquired a new stake in Editas Medicine, Inc. (NASDAQ: EDIT) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 10,589,990 shares of the company's stock, valued at approximately $34,312,000. BlackRock Inc. owned approximately 10.82% of Editas Medicine at the
CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that management will participate in the following upcoming investor conferences in September: Wells Fargo Healthcare Conference Format: Fireside ChatDate: Tuesday, September 8Time: 4:30 p.m.
Here is how Editas Medicine (EDIT) and Amylyx Pharmaceuticals, Inc. (AMLX) have performed compared to their sector so far this year.
EDIT-401 on track for CTN submission this month with data update in Q1 2027 Recently presented pre-clinical data demonstrating ~90% or greater mean reduction in multiple atherogenic lipoproteins, including LDL-C, Lp(a) and ApoB with EDIT-401 in non-human primates Recent financing strengthens Company's capital position, supporting continued advancement of EDIT-401 program, with cash runway into the second half of…
Recognized leader in cardiovascular medicine and human genetics brings extensive experience spanning scientific innovation, therapeutic discovery, and clinical leadership as Editas advances EDIT-401 to the clinic Recognized leader in cardiovascular medicine and human genetics brings extensive experience spanning scientific innovation, therapeutic discovery, and clinical leadership as Editas advances EDIT-401 to the…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.